US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Arovella Therapeutics Limited (ALAO) 銘柄情報

Arovella Therapeutics Limited (ALAO)

0.01

0.00

(0.00%)

終了 7月3日 3:00PM

Arovella Therapeutics Limited (ALAO) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.01

( - )

買値

0.01

売値

0.015

出来高

0.00

0.00 日の範囲 0.00

0.01 52 週間の範囲 0.04

時価総額

前日終値

0.01

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 1,068,872

発行済株式数

1,208,783,672

配当利回り

PER

-9.73

1 株当たり利益 (EPS)

-0.01

歳入

3.21M

純利益

-7.93M

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas ... Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.arovella.com

本社

Preston, Australia

設立

1999

Arovella Therapeutics Limited is listed in the sector of the オーストラリア証券取引所 with ticker ALAO. The last closing price for Arovella Therapeutics was AUD0.01. Over the last year, Arovella Therapeutics shares have traded in a share price range of AUD 0.01 to AUD 0.04.

Arovella Therapeutics currently has 1,208,783,672 shares in issue. The market capitalisation of Arovella Therapeutics is AUD12.09 million. Arovella Therapeutics has a price to earnings ratio (PE ratio) of -9.73.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.002	-16.6666666667	0.012	0.015	0.01	56719	0.01026544	DE
4	-0.003	-23.0769230769	0.013	0.015	0.01	145564	0.01306566	DE
12	-0.012	-54.5454545455	0.022	0.025	0.01	264922	0.01501478	DE
26	-0.014	-58.3333333333	0.024	0.031	0.01	282255	0.01843854	DE
52	-0.023	-69.696969697	0.033	0.04	0.01	264122	0.02317406	DE
156	-0.025	-71.4285714286	0.035	0.04	0.01	285910	0.02511975	DE
260	-0.025	-71.4285714286	0.035	0.04	0.01	285910	0.02511975	DE

ALAO - Frequently Asked Questions (FAQ)

What is the current Arovella Therapeutics Limited share price?

The current share price of Arovella Therapeutics Limited is AUD 0.01

How many Arovella Therapeutics Limited shares are in issue?

Arovella Therapeutics Limited has 1,208,783,672 shares in issue

What is the market cap of Arovella Therapeutics Limited?

The market capitalisation of Arovella Therapeutics Limited is AUD 12.09M

What is the 1 year trading range for Arovella Therapeutics Limited share price?

Arovella Therapeutics Limited has traded in the range of AUD 0.01 to AUD 0.04 during the past year

What is the PE ratio of Arovella Therapeutics Limited?

The price to earnings ratio of Arovella Therapeutics Limited is -9.73

What is the cash to sales ratio of Arovella Therapeutics Limited?

The cash to sales ratio of Arovella Therapeutics Limited is 24.86

What is the registered address of Arovella Therapeutics Limited?

The registered address for Arovella Therapeutics Limited is Corporate One, Preston, Victoria, 3072

What is the Arovella Therapeutics Limited website address?

The website address for Arovella Therapeutics Limited is www.arovella.com

Mister4

Mister4 3分前

Yes, absolutely correct, but that does not mean it stops there. It's been 17 years and the scams continue.

wadegarret

wadegarret 4分前

Value- Just curious

What % of your portfolio is in AI or AI related stocks ?

mm41

Warning: The End
The statistics are brutal: 80-90% of retail options traders lose money. Of the ones who “triple their portfolio”, half of them blow up their account in 6 months, and the other half goes quiet and deletes Twitter.
Why? Because leaps are a time bomb. Selling puts is like

brazen22

brazen22 5分前

The one item missing from your list is an approved MAA.

That is not a minor omission. That is the whole point.

If all of those items prove the case is so obvious, then why has MHRA still not approved after more than 2.5 years on an application submitted under the 150-da

Mister4

Mister4 5分前

Tired of all the excuses over the years. There is always a reason they cannot end the crime, but in reality they like what they have stolen, and they don't want to give it back.

Mister4

Mister4 7分前

It's hard to celebrate after knowing what the government has done here, the magnitude of the theft, the audacity of the leadership. The companies were sold, seized back, profits stolen and now will be sold a second time. That is like communism on steroids. We want to defeat it but in communist fashi

bubba412

bubba412 7分前

If you have 500,000 shares and just want a dollar a share you’ll have 500,000 dollars If you get a 15 to 1 split you wind up with 33,333 shares at 4.00 you have what we have now If it does to 10.00 like he said you have 330 thousand dollars Much less than it going to a dollar now

scoobey-do

scoobey-do 10分前

Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation

Roadmap Highlights Multiple AI-Driven Growth Initiatives Designed to Expand the Company's Technology Platform and Long-Term Market Opportunity

TORONTO, ON

scoobey-do

scoobey-do 10分前

Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation

Roadmap Highlights Multiple AI-Driven Growth Initiatives Designed to Expand the Company's Technology Platform and Long-Term Market Opportunity

TORONTO, ON

againstallodds

againstallodds 10分前

Lazerson sure ecstatic to read that !

https://investorshub.advfn.com/uimage/uploads/2026/7/3/imefuIMG_0494.jpeg

Truthsocial

Truthsocial 10分前

HIGH CHANCE OF APPROVAL....imo
Listen to the regulatory experts not fudsters.....

The chances for Vivos Inc (RDGL) to receive approval for its Early Feasibility Study (EFS) Investigational Device Exemption (IDE) are considered highly favorable by investors and regulatory exper

Just give me $1.50

Just give me $1.50 13分前

Why was my account suspended for one week?

Thanks.

manibiotech

manibiotech 14分前

Anyone has access to what was presented ?

pdicamillo1

pdicamillo1 15分前

It certainly looks like the writeup created some volume and upward price momentum. Can you let us know when specifically that writeup was published and share what was written? Was is published as one of the main companies that MicroCap Club profiles or just simply shared with members from the foru

cabos_tacos

cabos_tacos 18分前

Waukeenah is just a few miles east of our home.. Sometimes we park across the highway where the Trulieve grow facility ( its huge) and when the winds are right.. roll down the windows and? After a few minutes, you're high and that pizza you brought tastes so good . hahaha

Goats'nCrows

Goats'nCrows 18分前

I can't speak to small pharma but Copy Review is a time consumer at BP and ultimately expensive. That makes me believe (that while I love your idea), that the company would pass.

(My personal speculation has always been that the CR process and its costs is why we have no much neede

PutzMueler

PutzMueler 23分前

ge11 I can’t get in and look at the full report, is it for the air permit? It does state click on air permit, but I thought once construction was started we did not need to apply again.

Also is DWEE the new NDEE for air permitting,

Or is this part of an ESIA applicat

jammy32

jammy32 23分前

If all of this is really happening, isn’t Nasrat accountable? He’s the CEO and he’s doing nothing to protect the PPS. 82 cents to 34 cents in 12 months and he laughs it off with his bs comments about the better we do the worse the stock does. Also, the 5 million really pisses me off

LocWolf

LocWolf 23分前

Chazzy and Alan...thank you.eom

OldAIMGuy

OldAIMGuy 24分前

Report on my Portfolios....................

My Twinvest IRA that I converted to AIM.....
https://investorshub.advfn.com/uimage/uploads/2026/7/3/klgtdSimpIRA.jpg
The VUG Growth fund stalled for June and so did the portfolio.

Business Sector ETFs (each manag

deri21

deri21 26分前

Nano / Micro / Small Cap Press Flashback 6/29 - 7/3

$SSII SS Innovations Named Outstanding Company Winner at the 2026 Surgical Robotics Industry Awards
https://www.globenewswire.com/news-release/2026/06/30/3319802/0/en/SS-Innovations-Named-Outstanding-Company-Winner-at-the-202

deri21

deri21 26分前

Nano / Micro / Small Cap Press Flashback 6/29 - 7/3

$SSII SS Innovations Named Outstanding Company Winner at the 2026 Surgical Robotics Industry Awards
https://www.globenewswire.com/news-release/2026/06/30/3319802/0/en/SS-Innovations-Named-Outstanding-Company-Winner-at-the-202

Wehalls

Wehalls 26分前

He is saying that current technology has made the patent obsolete and it doesn't reflect how he is currently doing business.

al507

and more Tx date: 2026-07-02
Filed: 2026-07-03 03:06

Neumeyer, Keith
4 - Director of Issuer
Common Shares
10 - Acquisition or disposition in the public market
$170,000
+250,000 vol
$0.6800 each
Direct Ownership
47,092,813

ARbigguy1

ARbigguy1 27分前

tombe, great question, the only answer as why is that there has been huge naked shorting going on all the way back to when ELTP moved to the OTC. Illegal short sellers love the OTC market because the SEC basically ignores all the rampant fraud on the OTC whether it is the fake companies or market m

Arovella Therapeutics

Wrst Fxd Cpn Atcl Nts Lk...

L3Harris Technologies

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。